ReviewF1000Research2019
Medicines in pregnancy.
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Regulation of Human Renal Transporters by Pregnancy-Related Hormones in Primary Proximal Tubular Epithelial Cells.Metabolites · 2026Article
- A White Paper on Advancing Long-Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation.Clinical pharmacology and therapeutics · 2026Review
- Microglia determine an immune-challenged environment and facilitate ibuprofen action in human retinal organoids.Journal of neuroinflammation · 2025Article
- A User-Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline.Clinical pharmacology and therapeutics · 2025Article
- Article
- Article
- Eliminating gender bias in biomedical research requires fair inclusion of pregnant women and gender diverse people.Communications medicine · 2024Review
- Endocrine disruption and male reproductive disorders: unanswered questions.Human reproduction (Oxford, England) · 2024Review
- Perceived barriers and facilitators for model-informed dosing in pregnancy: a qualitative study across healthcare practitioners and pregnant women.BMC medicine · 2024Article
- Assessment of knowledge, attitude, and practice on self-care with over-the-counter medicines among pregnant women.Exploratory research in clinical and social pharmacy · 2024Article
- Assessment of self-medication practices and safety profile of medicines utilisation among pregnant women attending antenatal clinics in Freetown, Sierra Leone: a multicentre cross-sectional study.Journal of pharmaceutical policy and practice · 2024Article
- The first review on prenatal drug exposure and ocular malformation occurrence.Frontiers in pediatrics · 2024Review
- Willingness-to-use and preferences for model-informed antenatal doses: a cross-sectional study among European healthcare practitioners and pregnant women.Frontiers in pharmacology · 2024Article
- Knowledge, attitude, and practice of medication use among pregnant women in Riyadh City: a cross-sectional study.Frontiers in global women's health · 2024Article
- Review
- Drug Prescriptions among Italian and Immigrant Pregnant Women Resident in Italy: A Cross-Sectional Population-Based Study.International journal of environmental research and public health · 2022Article
- Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries.International journal of environmental research and public health · 2022Article
- Grandmothers' endocrine disruption during pregnancy, low birth weight, and preterm birth in third generation.International journal of epidemiology · 2022Article
- Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies.F1000Research · 2022Article
- Identification of At-risk Pregnant Population for Over-the-Counter Drug Usage in Low-Resource Settings.Journal of obstetrics and gynaecology of India · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women's long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.